TrialLeukemia research2021

Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.

Eric Huselton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.